Milestone Pharmaceuticals Inc. filings document a commercial-stage biopharmaceutical company focused on cardiovascular medicines, including CARDAMYST (etripamil) nasal spray for adults with PSVT. Its 8-K filings report financial results, commercial launch updates, regulatory and corporate updates, Regulation FD presentations and material events related to etripamil.
The filing record also covers Milestone's Nasdaq-listed common shares, proxy governance for annual shareholder meetings, board and voting matters, and capital-structure items such as the completed sale of a royalty interest tied to U.S. etripamil net product sales. These disclosures provide formal records of operating results, governance, financing arrangements and product-related corporate events.
Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Commercial Officer. On February 2, 2026, the officer received an employee stock option to purchase 204,000 common shares at an exercise price of $1.96 per share, correcting an exercise price that had been stated incorrectly in initial filings.
According to the vesting schedule, one-fourth of the option shares vest on February 2, 2027, with one thirty-sixth of the remaining shares vesting monthly thereafter, as long as the officer continues providing service. Following this grant, the officer beneficially owns 204,000 stock options, held directly.
Milestone Pharmaceuticals Inc. insider filing: the company’s CFO and EVP of Corporate Development reported an amended employee stock option grant. The filing corrects the exercise price for an option to buy 204,000 common shares at $1.96 per share, granted on February 2, 2026 and expiring on February 2, 2036. One-fourth of the option vests on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months while the executive continues providing service.
Milestone Pharmaceuticals granted its Chief Commercial Officer, Lorenz Muller, new equity awards. On February 2, 2026, he received an employee stock option for 204,000 common shares at an exercise price of $1.97 per share. One-fourth of these option shares vest on February 2, 2027, and the remaining shares vest in equal monthly installments over the following thirty-six months, as long as he continues providing service.
He was also granted 136,000 restricted stock units on the same date, each representing the right to receive one common share. These RSUs vest in four equal installments on February 2 of each year from 2027 through 2030, again contingent on continued service. After these grants, he beneficially owns all 204,000 option awards and 136,000 RSUs directly.
Milestone Pharmaceuticals Inc. granted new equity awards to its CFO and EVP of Corporate Development, Amit Hasija. On February 2, 2026, he received an employee stock option covering 204,000 common shares at an exercise price of $1.97 per share, expiring on February 2, 2036. One-fourth of these option shares vest on February 2, 2027, with the remaining shares vesting monthly over the following 36 months, contingent on continued service. He also received 136,000 restricted stock units, each representing one common share. These RSUs vest in four equal annual installments on February 2 of 2027, 2028, 2029, and 2030, also subject to continued service.
Milestone Pharmaceuticals Inc. reported that its Chief Operating Officer, Jeffrey Edward Nelson, received new equity awards. On February 2, 2026, he was granted an option to buy 204,000 common shares at $1.97 per share and 136,000 restricted stock units.
One-fourth of the option vests on February 2, 2027, with the remaining shares vesting monthly over three years, contingent on continued service. The RSUs vest in four equal annual installments on February 2 of 2027, 2028, 2029, and 2030, also subject to continued service.
Milestone Pharmaceuticals Inc. reported new equity awards to Chief Medical Officer David Bharucha. On February 2, 2026, he received an employee stock option covering 204,000 common shares at an exercise price of $1.97 per share, expiring February 2, 2036.
One-fourth of the option vests on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months, assuming continued service. He also received 136,000 restricted stock units, each representing one common share, vesting in four equal annual installments on February 2 of 2027, 2028, 2029 and 2030, subject to continued service.
Milestone Pharmaceuticals Inc. President and CEO Joseph Oliveto reported new equity awards. On February 2, 2026, he was granted an employee stock option for 679,000 common shares at an exercise price of $1.97 per share and a restricted stock unit award covering 453,000 common shares.
Both awards are held directly and vest over several years. The option vests 25% on February 2, 2027, with the remaining option shares vesting monthly over the following 36 months. The restricted stock units vest in four equal annual installments from February 2, 2027 through February 2, 2030, contingent on continued service.
Milestone Pharmaceuticals Chief Medical Officer David Bharucha reported new equity awards and related share sales. On December 12, 2025, he acquired 100,000 performance stock units (PSUs) that vested when the FDA granted a New Drug Application approval letter for Cardamyst (etripamil), and he also received an option for 100,000 common shares at an exercise price of $1.74, vesting in two equal installments in 2026. On December 15, 2025, he sold 58,007 common shares at a weighted average price of $2.32 under a sell-to-cover arrangement for taxes. On January 26, 2026, 20,100 restricted stock units were converted into common shares, followed by the sale of 12,245 shares at a weighted average price of $1.93, also to cover tax liabilities. After these transactions, he directly owned 113,181 common shares and 60,300 restricted stock units, with remaining RSUs vesting in annual installments through 2029.
Milestone Pharmaceuticals Inc. Chief Operating Officer Nelson Jeffrey Edward reported multiple equity award events tied to Cardamyst (etripamil). A 100,000-share performance stock unit award vested after FDA New Drug Application approval of Cardamyst, with each PSU delivering one common share. He also received an option for 100,000 common shares at $1.74 per share, vesting in two equal installments on June 12, 2026 and December 12, 2026, subject to continued service. On January 26, 2026, 20,100 restricted stock units converted into common shares, and 12,245 shares were sold at a weighted average price of $1.93 under a sell-to-cover arrangement to satisfy tax liabilities, following an earlier 58,007-share sell-to-cover sale at $2.32 on December 15, 2025.
Milestone Pharmaceuticals Chief Commercial Officer Muller Lorenz reported multiple equity compensation events tied to regulatory and service milestones. On December 12, 2025, a performance stock unit award for 100,000 common shares vested after the U.S. Food and Drug Administration issued a New Drug Application Approval Letter for Cardamyst (etripamil), and a separate employee stock option for 100,000 shares with a $1.74 exercise price was granted, vesting in two halves on June 12, 2026 and December 12, 2026.
On January 26, 2026, 20,100 restricted stock units converted into common shares as part of an award that vests in four annual installments through January 26, 2029. Shares totaling 53,566 at a weighted average price of $2.32 and 11,180 at $1.93 were sold solely to cover tax liabilities from PSU and RSU vesting. After these transactions, Lorenz directly owned 205,406 common shares, 100,000 stock options, and 60,300 restricted stock units.